To investigate the effects of JUN ablation in vitro, we utilized the CRISPR/Cas9 technology in the human PCa cell lines DU145 (PTEN wildtype) and PC3 (PTEN mutated). The gene discussed is JUN; the disease is posterior cortical atrophy.